Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-92.04% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
AUPH · Mar 31, 2023
Aurinia Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001600620-23-000012General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
59.12% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
92.26% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
98.78% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-85.98% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
38.24% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
27.51% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History12 statesSelf-history eligible
Mar 31, 20210/6 normalizedLevel 3Jun 30, 20210/6 normalizedLevel 3Sep 30, 20210/6 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20225/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Sep 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- -59.34%
- Current
- -92.04%
- Delta
- -32.70%
- Previous
- 193.89%
- Current
- 59.12%
- Delta
- -134.78%
- Previous
- 18.47%
- Current
- 92.26%
- Delta
- 73.79%
- Previous
- 95.77%
- Current
- 98.78%
- Delta
- 3.00%
- Previous
- -83.17%
- Current
- -85.98%
- Delta
- -2.81%
- Previous
- 33.57%
- Current
- 38.24%
- Delta
- 4.67%
- Previous
- 24.10%
- Current
- 27.51%
- Delta
- 3.41%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · AUPH Fundamental State →Has State · Aurinia Pharmaceuticals Inc. →Transitioned To · AUPH Fundamental State →Transitioned To · AUPH CASH_GENERATION_DECREASED →Transitioned To · AUPH GROWTH_DECREASED →Transitioned To · AUPH INVENTORY_PRESSURE_INCREASED →Transitioned To · AUPH MARGIN_INCREASED →Transitioned To · AUPH PROFITABILITY_DECREASED →Transitioned To · AUPH R_AND_D_INTENSITY_INCREASED →Transitioned To · AUPH SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.